PubMed Health⌕ Search

Biomedical subjects

A K Robison

Publications and source records attributed to A K Robison.

15 recordsLinked to original sources

Intramuscular administration of human tissue-type plasminogen activator in rabbits and dogs and its implications for coronary thrombolysis.

To determine whether sustained plasma concentration of human tissue-type plasminogen activator (t-PA) can be induced promptly after intramuscular injection with enhancers of absorption devoid of deleterious local and systemic effects, we studied 250 rabbits and 13 dogs. In rabbits with t-PA injected directly into exposed muscle followed by local electrical stimulation at the site, early absorption was increased markedly by addition of 0.63M methylamine plus 0.079M hydroxylamine to the excipient. Elevations peaked within 5 min and increased with dose of t-PA, concentration of methylamine, and volume of injection medium. The enhancers were effective with percutaneous injections in the absence of local electrical stimulation as well. They did not elicit any obviously deleterious local or systemic effects. In separate experiments in rats, intramuscular injections of 0.63M methylamine plus 0.079M hydroxylamine induced local egress of intravascular radiolabeled albumin within the injection site and endothelial gaps in venules detected with colloidal carbon--changes consistent with direct effects on vascular permeability. In dogs, percutaneous intramuscular injection of t-PA in excipient without enhancers did not lead to early elevations of human t-PA in plasma, although late elevations were seen. When the enhancers were used, early elevations occurred as well, with functional activity documented by fibrin plate assays of serially obtained plasma samples and by sequential coronary angiography delineating thrombolysis after experimentally induced coronary thrombosis. The results indicate that intramuscular administration of t-PA with selected enhancers of absorption is a feasible approach for rapid induction of fibrinolysis.

Absorption↗

Clinical pharmacology of coronary thrombolysis.

Pharmacologic thrombolysis is dependent on activation of endogenous plasminogen to the active proteolytic enzyme, plasmin. Agents such as tissue-plasminogen activator with a high affinity for fibrin bound plasminogen result in high local concentration of plasmin. Thus, they achieve clot lysis with less tendency to induce a systemic lytic state reflecting extensive fibrinogenolytic activity in the circulation. Appropriate dose regimens for thrombolytic agents in specific clinical situations is critical to maximize therapeutic efficacy while minimizing the risk of significant bleeding.

Coronary Disease↗

Activation of the fibrinolytic system.

The fibrinolytic system is activated either directly or indirectly by proteins that convert plasminogen to plasmin in the circulation, within the interstitices, and on the surface of fibrin clots, or both. Agents that activate circulating and clot-bound plasminogen comparably induce a systemic lytic state accompanying clot lysis. Agents that activate plasminogen in the domain of fibrin preferentially exhibit clot selectivity. Fibrinolytic activators are assayed by detection of protein, generally immunologically, or of functional activity, generally by visualization of lysis of fibrin or by spectrophotometric determination of amidolytic activity.

Acylation↗

Pharmacodynamics of tissue-type plasminogen activator characterized by computer-assisted simulation.

Prospective characterization of pharmacodynamics of tissue-type plasminogen activator (t-PA) is needed for diverse clinical applications. Accordingly, we used physiologically based, computer simulation of participating biochemical reactions in response to concentrations of circulating t-PA seen with infusions of 1 to 7 hr duration in 45 patients. Predicted values were compared with those from a "training set" obtained in six patients given t-PA for coronary thrombosis and six receiving therapy for peripheral arterial occlusion. Subsequently, results of simulation were compared prospectively with observations from a "test set" of 33 consecutive patients given low doses of t-PA for as long as 7 hr or higher doses for 1 to 2 hr and with data from 101 patients given t-PA in the European Cooperative Trial. Fits between observed and predicted values were close. Based on observations in the training set, the alpha 2-macroglobulin reaction with circulating plasmin and ongoing synthesis of plasminogen were incorporated in the simulations. Fibrinogenolysis in vitro was documented despite supplementation of samples with aprotinin, particularly when concentrations of t-PA were high. This phenomenon can lead to overestimation of fibrinogen depletion and was found to be obviated by the use of PPACK, a novel serine protease inhibitor. Results indicate that the simulation approach developed permits economic, prospective evaluation of regimens of t-PA suitable for diverse conditions and delineation of the impact of individual constituents and reactions on pharmacodynamics of t-PA and on the risk of induction of a systemic lytic state.

Adult↗

DDT supports the growth of an estrogen-responsive tumor.

MT2 cells, a clonal cell line of MTW9/PL cells originally obtained from a mammary adenocarcinoma, from estrogen-responsive tumors in Wistar-Furth rats. o,p'-DDT supports MT2 tumor growth at a rate similar to 17 beta-estradiol. This effect of o,p'-DDT is dose-dependent and specific, since the DDT congener p,p'-DDD, which does not bind to tumor estrogen receptors, does not support tumor growth. This is the first demonstration that DDT can support the growth of an estrogen-responsive tumor.

Adenocarcinoma↗

Coronary thrombolysis with facilitated absorption of intramuscularly injected tissue-type plasminogen activator.

Conventional activators of the fibrinolytic system used for coronary thrombolysis entail unavoidable delay, risk of bleeding, or both in contrast to tissue-type plasminogen activator (t-PA). Because the potential benefit of coronary thrombolysis is inversely related to the duration of antecedent ischemia, this study was performed to develop an approach for facilitated absorption of intramuscularly injected t-PA potentially adaptable for prompt, self-medication. In rabbits, absorption was markedly potentiated by hydroxylamine hydrochloride and electrical stimulation at the injection site. Intramuscular administration of t-PA in doses of 1 mg/kg of body weight, comparable to amounts given intravenously to patients (0.5-0.75 mg/kg), elicited peak blood levels of 431 +/- 52 (SEM) ng/ml 5 min after injection, well within the therapeutic range. In dogs, absorption facilitated by hydroxylamine promptly elicited angiographically documented coronary thrombolysis as well. The approach developed should ultimately permit prompt coronary thrombolysis and enhanced salvage of jeopardized ischemic myocardium in patients with life-threatening coronary thrombi.

Animals↗

Estrogenic activity of DDT: estrogen-receptor profiles and the responses of individual uterine cell types following o,p'-DDT administration.

The administration of o,p'-dichlorodiphenyltrichloroethane (o,p'-DDT) to immature rats stimulates DNA synthesis and cell division in the uterine luminal epithelium (LE), stroma (S), and myometrium (M). The time course of DNA synthesis/cell division in the S and M is similar following administration of o,p'-DDT or 17 beta-estradiol, but the maximum response following pesticide treatment is only 70% of that produced by the hormone. In the LE both compounds yield the same maximum response, but the time course of DNA synthesis/cell division is delayed following o,p'-DDT administration relative to 17 beta-estradiol treatment. The patterns of estrogen receptor retention in uterine nuclei following o,p'-DDT administration are prolonged relative to those observed after 17 beta-estradiol treatment. o,p'-DDT thus produces the uterine hyperplasia characteristic of estrogens, but the magnitude and timing of the response is dependent on the specific cell type observed and is different from that produced by estradiol.

Animals↗

Prevention of coronary thrombosis with subthrombolytic doses of tissue-type plasminogen activator.

To determine whether tissue-type plasminogen activator (t-PA) may prevent coronary thrombosis or accelerate the lysis of clot formed under conditions in which increased concentration of the activator is present before thrombosis, clot lysis studies were undertaken in vitro and in vivo. In vitro, exogenous t-PA (6 to 100,000 ng/ml) accelerated the lysis of clot in a dose-dependent fashion when the clot was formed either from whole plasma or from euglobulin fractions (n = 316 determinations). Adding t-PA before clot formation shortened the time to lysis by at least threefold with euglobulin fractions and by at least 10-fold with whole plasma clots, which is consistent with the presence of inhibitors of fibrinolysis in whole plasma and with the binding of t-PA to nascent fibrin. In an intact dog preparation of coronary thrombosis (n = 25), occlusive thrombus formation was prevented when t-PA was present in subthrombolytic concentrations (430 to 1200 ng/ml, n = 5). Occlusive thrombus formation occurred after only discontinuation of the t-PA infusion and clearance of t-PA. Lower concentrations of t-PA (147 to 427 ng/ml, n = 6) significantly delayed occlusion (26 +/- 6.5 vs 7.8 +/- 2.8 min for controls). In animals with t-PA concentrations of less than 140 ng/ml (n = 4), the time to occlusion was unaltered (7.7 +/- 4.5 min). The present study demonstrates that t-PA present before clot formation inhibits thrombosis or accelerates thrombolysis depending on concentration, and that subthrombolytic doses of t-PA can prevent thrombus formation in vivo.(ABSTRACT TRUNCATED AT 250 WORDS)

Animals↗

The estrogenic activity of DDT: the in vitro induction of an estrogen-inducible protein by o,p'-DDT.

Induced protein is a commonly measured marker for estrogenic action. The induction of induced protein by o,p'-DDT was studied in an in vitro system. Nuclear levels of estrogen receptor translocated by o,p'-DDT correlated highly with induced protein induction, and the time course for induced protein induction was consistent with an estrogen receptor-mediated mechanism. While the maximum amount of induced protein produced by o,p'-DDT was less than after 17 beta-estradiol exposure, the induced protein formed by each compound was indistinguishable on nondenaturing and denaturing polyacrylamide gels. Also, it was shown that o,p'-DDT does not cause additional induction of induced protein over that seen with maximum levels of 17 beta-estradiol, further supporting the premise that these compounds share a common pathway in stimulating the synthesis of induced protein.

Animals↗

The estrogenic activity of DDT: correlation of estrogenic effect with nuclear level of estrogen receptor.

Administration of o,p'-DDT to immature female rats causes a translocation of estrogen receptors to uterine nuclei which is maximum 3 hours after pesticide treatment, and a subsequent increase in uterine weight at 24 hours. A high degree of correlation (r = 0.98) exists between the level of nuclear estrogen receptor and increases in uterine weight measured 3 and 24 hours respectively after administration of o,p'-DDT, in the dose range of 10-1000 mg/kg. This high degree of correlation between these two parameters lends strong support to the hypothesis that the estrogenic effects observed following in vivo administration of o,p'-DDT result from the interaction of the pesticide with the classical estrogen receptor system.

Animals↗

Accumulation of lysophosphoglycerides with arrhythmogenic properties in ischemic myocardium.

Lysophosphoglycerides, products of membrane phospholipid catabolism known to influence membrane function in several systems, appeared in the effluents of anoxic isolated rabbit hearts perfused at low flow and accumulated in perfused hearts and myocardium rendered ischemic in situ. Comparable concentrations of lysophosphoglycerides bound to albumin markedly and reversibly altered action potentials of isolated canine Purkinje fibers in vitro. Changes induced included diminution of the maximum diastolic potential, peak dV/dt of phase zero, amplitude, and action potential duration--alterations resembling those seen in ischemic myocardium in vivo. These electrophysiological alterations are compatible with changes implicated in predisposing to dysrhythmia dependent on reentry, a phenomenon potentiated by the presence of zones of decreased conduction. Thus, accumulation of lysophosphoglycerides induced by ischemia may contribute to the genesis of malignant dysrhythmia early after its onset.

Action Potentials↗